Functional imaging and circulating biomarkers of response to regorafenib in treatment-refractory metastatic colorectal cancer patients in a prospective phase II study
Khurum Khan(Institute of Cancer Research), Nicola Valeri(Royal Marsden NHS Foundation Trust), Massimo Rugge(University of Padua), Nicos Fotiadis(Royal Marsden NHS Foundation Trust), George Vlachogiannis(Institute of Cancer Research), Andrea Lampis(Institute of Cancer Research), Ian Chau(Royal Marsden NHS Foundation Trust), Jens C. Hahne(Institute of Cancer Research), Dow‐Mu Koh(Royal Marsden NHS Foundation Trust), Matteo Fassan(University of Padua), Mahnaz Darvish-Damavandi(Institute of Cancer Research), Chiara Braconi(Beatson West of Scotland Cancer Centre), Eleftheria Kalaitzaki(University College London), Silvia Marchetti(Institute of Cancer Research), David J. Collins(Engineering and Physical Sciences Research Council), Nina Tunariu(Leicester Royal Infirmary), David Cunningham(Royal Marsden NHS Foundation Trust), Anja Williams(Sarah Cannon Research Institute), Maria Antonietta Bali(Royal Marsden NHS Foundation Trust), Mihaela Rata(Royal Marsden Hospital), Hazel Lote(Institute of Cancer Research), Somaieh Hedayat(Institute of Cancer Research), David Watkins, Eleanor Temple(Royal Marsden NHS Foundation Trust), Zakaria Eltahir(Royal Marsden NHS Foundation Trust), Ruwaida Begum, Sheela Rao(Royal Marsden NHS Foundation Trust), Suzanne A. Eccles(Discovery Centre), J.M. Thomas(Royal Marsden NHS Foundation Trust), Elisa Fontana(Sarah Cannon Research Institute), Isma Rana(Royal Marsden NHS Foundation Trust), Naureen Starling(Royal Marsden NHS Foundation Trust)
Cited by 73
Related Papers
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
|New England Journal of Medicine|2010|4.5k
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Cholangiocarcinoma 2020: the next horizon in mechanisms and management
|Nature Reviews Gastroenterology & Hepatology|2020|2.5k
Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
|New England Journal of Medicine|2008|2.3k
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
|New England Journal of Medicine|2015|2.2k